Purpose and goals
Use of Big Data for further purposes ("secondary data") as well as new methods such as machine learning and the use of artificial intelligence are fields that are also rapidly growing in the healthcare sector. The resulting opportunities are being pursued vigorously in the medical field in order to improve public healthcare continuously and the HDL plays a crucial role in this development. The HDL is a successor to the former Data Preparation Centre ("Datenaufbereitungsstelle") which has been enabling data analyses of medical claims data for research purposes since 2013. The establishment of the HDL was initiated by legislature in 2019 through the Digital Healthcare Act while the Data Transparency Ordinance (DaTraV) specifies the corresponding legal regulations. Located at the Federal Institute for Drugs and Medical Devices, the HDL fulfills its tasks independently and autonomously. In the future, researchers from authorised institutions will be able to evaluate data in the controlled analysis environment of the HDL. Authorised users include leading federal organisations that represent the interests of patients and self-help groups for the chronically ill as well as for people with disabilities.The analyses are expected both to result in a variety of scientific publications and to contribute to the improvement of the medical care system.
New HDL currently being established
The new Health Data Lab is currently in the process of being established which will take place in phases. Unfortunately, no applications can be submitted at this time. First, the legal, technical personnel and organisational measures of the new HDL must be defined and implemented. It is expected that applications can be submitted online in the second half of 2024.